vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and OGE ENERGY CORP. (OGE). Click either name above to swap in a different company.

OGE ENERGY CORP. is the larger business by last-quarter revenue ($752.6M vs $406.6M, roughly 1.9× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 6.7%, a 53.8% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 0.7%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 8.1%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Oklahoma Gas & Electric Company is a regulated electric utility company that serves over 843,000 customers in Oklahoma and Arkansas, including 1.5 million people in the Oklahoma City Metropolitan Area. It is the leading subsidiary of OGE Energy Corp., with headquarters in downtown Oklahoma City. OGE Energy is also the former parent of Enogex Inc., a natural gas pipeline business which merged with CenterPoint Energy's midstream business to form Enable Midstream in 2013, in 2021 OGE and CenterP...

BCRX vs OGE — Head-to-Head

Bigger by revenue
OGE
OGE
1.9× larger
OGE
$752.6M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+208.4% gap
BCRX
209.1%
0.7%
OGE
Higher net margin
BCRX
BCRX
53.8% more per $
BCRX
60.5%
6.7%
OGE
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
8.1%
OGE

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
OGE
OGE
Revenue
$406.6M
$752.6M
Net Profit
$245.8M
$50.2M
Gross Margin
97.7%
Operating Margin
64.0%
15.0%
Net Margin
60.5%
6.7%
Revenue YoY
209.1%
0.7%
Net Profit YoY
1017.5%
-19.9%
EPS (diluted)
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
OGE
OGE
Q1 26
$752.6M
Q4 25
$406.6M
$701.7M
Q3 25
$159.4M
$1.0B
Q2 25
$163.4M
$719.7M
Q1 25
$145.5M
$741.1M
Q4 24
$131.5M
$744.7M
Q3 24
$117.1M
$945.2M
Q2 24
$109.3M
$644.1M
Net Profit
BCRX
BCRX
OGE
OGE
Q1 26
$50.2M
Q4 25
$245.8M
$69.2M
Q3 25
$12.9M
$231.3M
Q2 25
$5.1M
$107.5M
Q1 25
$32.0K
$62.7M
Q4 24
$-26.8M
$101.9M
Q3 24
$-14.0M
$218.7M
Q2 24
$-12.7M
$102.3M
Gross Margin
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
97.7%
59.2%
Q3 25
98.6%
62.2%
Q2 25
98.3%
63.7%
Q1 25
96.9%
56.3%
Q4 24
95.4%
59.7%
Q3 24
97.3%
63.0%
Q2 24
98.4%
69.9%
Operating Margin
BCRX
BCRX
OGE
OGE
Q1 26
15.0%
Q4 25
64.0%
19.7%
Q3 25
18.6%
33.2%
Q2 25
18.2%
25.9%
Q1 25
14.6%
18.0%
Q4 24
-3.4%
24.5%
Q3 24
6.6%
33.1%
Q2 24
8.0%
27.3%
Net Margin
BCRX
BCRX
OGE
OGE
Q1 26
6.7%
Q4 25
60.5%
9.9%
Q3 25
8.1%
22.5%
Q2 25
3.1%
14.9%
Q1 25
0.0%
8.5%
Q4 24
-20.4%
13.7%
Q3 24
-12.0%
23.1%
Q2 24
-11.6%
15.9%
EPS (diluted)
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$1.13
$0.34
Q3 25
$0.06
$1.14
Q2 25
$0.02
$0.53
Q1 25
$0.00
$0.31
Q4 24
$-0.13
$0.50
Q3 24
$-0.07
$1.09
Q2 24
$-0.06
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
OGE
OGE
Cash + ST InvestmentsLiquidity on hand
$274.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-119.2M
Total Assets
$514.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$274.7M
$200.0K
Q3 25
$212.9M
$300.0K
Q2 25
$260.0M
$500.0K
Q1 25
$295.1M
$26.9M
Q4 24
$320.9M
$600.0K
Q3 24
$96.8M
$9.9M
Q2 24
$78.4M
$100.0K
Total Debt
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$5.4B
Q3 25
Q2 25
Q1 25
Q4 24
$5.1B
Q3 24
Q2 24
Stockholders' Equity
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$-119.2M
$5.0B
Q3 25
$-387.9M
$4.8B
Q2 25
$-421.6M
$4.6B
Q1 25
$-451.9M
$4.6B
Q4 24
$-475.9M
$4.6B
Q3 24
$-468.6M
$4.6B
Q2 24
$-475.6M
$4.5B
Total Assets
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$514.2M
$14.4B
Q3 25
$446.4M
$14.3B
Q2 25
$457.2M
$14.1B
Q1 25
$480.0M
$14.0B
Q4 24
$490.4M
$13.7B
Q3 24
$491.3M
$13.5B
Q2 24
$472.4M
$13.2B
Debt / Equity
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
1.08×
Q3 25
Q2 25
Q1 25
Q4 24
1.09×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
OGE
OGE
Operating Cash FlowLast quarter
$292.0M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$292.0M
$384.8M
Q3 25
$41.6M
$397.8M
Q2 25
$41.3M
$338.6M
Q1 25
$-27.5M
$15.9M
Q4 24
$-5.2M
$129.6M
Q3 24
$8.2M
$347.1M
Q2 24
$-1.4M
$253.1M
Free Cash Flow
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
$291.2M
$83.1M
Q3 25
$40.3M
$168.3M
Q2 25
$41.1M
$64.9M
Q1 25
$-27.7M
$-233.6M
Q4 24
$-5.9M
$-167.0M
Q3 24
$8.2M
$103.0M
Q2 24
$-1.5M
$-70.2M
FCF Margin
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
71.6%
11.8%
Q3 25
25.3%
16.4%
Q2 25
25.2%
9.0%
Q1 25
-19.0%
-31.5%
Q4 24
-4.5%
-22.4%
Q3 24
7.0%
10.9%
Q2 24
-1.4%
-10.9%
Capex Intensity
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
0.2%
43.0%
Q3 25
0.8%
22.3%
Q2 25
0.1%
38.0%
Q1 25
0.1%
33.7%
Q4 24
0.5%
39.8%
Q3 24
0.1%
25.8%
Q2 24
0.1%
50.2%
Cash Conversion
BCRX
BCRX
OGE
OGE
Q1 26
Q4 25
1.19×
5.56×
Q3 25
3.23×
1.72×
Q2 25
8.12×
3.15×
Q1 25
-859.91×
0.25×
Q4 24
1.27×
Q3 24
1.59×
Q2 24
2.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

Segment breakdown not available.

OGE
OGE

Residential$260.4M35%
Commercial$212.0M28%
Public authorities and street light$61.9M8%
Industrial$60.7M8%
Oilfield$58.4M8%
Integrated market$47.3M6%
Transmission$40.7M5%

Related Comparisons